# ERCC1 Targeted Trial

> **NCT00801736** · PHASE3 · TERMINATED · sponsor: **University College, London** · enrollment: 648 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Cisplatin, Paclitaxel

## Key facts

- **NCT ID:** NCT00801736
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2013-07
- **Final completion:** —
- **Target enrollment:** 648 (ACTUAL)
- **Why stopped:** The antibody used did not appear prognostic/predictive based on interim results.
- **Last updated:** 2013-12-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00801736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00801736, "ERCC1 Targeted Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00801736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*